Watson Pharmaceutical Uracyst Trial


Watson Pharmaceuticals is currently recruiting participants for a clinical trial (#NCT00919113) studying the effectiveness of the new product, Uracyst, for its safety and effectiveness in IC/PBS patients.

Uracyst is a bladder instillation product. The active ingredient in Uracyst is sterile sodium chondroitin sulphate, a substance found naturally in the body-including the bladder. The study aims to evaluate the effectiveness of Uracyst by comparing the effects of this product when compared to placebo. Participation in this trial will involve one initial screening visit 8 weekly instillation visits, and 4 additional follow-up visits.

Approximately 20 sites in 14 states are now actively recruiting women who are at least 18 years of age and have been diagnosed with IC/PBS to take part in this study. Subjects who take part in this trial will receive study medication and all study-related procedures free of charge. Please visit the study website to see a complete list of exclusion criteria as well as a list of participating sites and contact information. Refer to the study number: NCT00919113.

Colorado:
    • Boulder (Recruiting)
    • Denver (Recruiting)

Connecticut:
    • Farmington (Recruiting)

Florida:
    • Plantation (Recruiting)
    • Wellington (Recruiting)

Georgia:
    • Columbus (Recruiting)

Idaho:
    • Coeur d’Alene (Recruiting)

Illinois:
    • Melrose Park (Recruiting)
    • Evanston (Recruiting)

Michigan:
    • Royal Oak (Recruiting)

Nevada:
    • Las Vegas (Recruiting)

New Jersey:
    • Englewood (Recruiting)
    • Sewell (Recruiting)
    • Westampton (Recruiting)

New York:
    • Albany (Recruiting)
    • Poughkeepsie (Recruiting)

North Carolina:
    • Winston-Salem (Recruiting)

Oklahoma:
    • Oklahoma City (Recruiting)

Pennsylvania:
    • Philadelphia (Recruiting)

Washington:
    • Mountlake Terrace (Recruiting)

www.clinicaltrials.gov


Revised September 23, 2009